Medication classes
Anti-integrin articles covering treatments such as vedolizumab and natalizumab, including safety, effectiveness, approvals, and access. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
10 articles
Cure8 found this source from caledonianrecord.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Crohn's disease, and Vedolizumab. Open the original article for the full details.
This could expand an approved, gut-targeted biologic (vedolizumab/ENTYVIO) to children as young as 2 with UC or Crohn’s disease, addressing a pediatric treatment gap if the FDA approves the sBLA. Families and clinicians...
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
Postoperative recurrence after ileocolonic resection is common in Crohn’s disease. This randomized trial suggests vedolizumab can reduce early endoscopic recurrence, offering an additional biologic option for preventing...
